Biology of Blood and Marrow Transplantation · 2010 · 100 citations · 46 references
MedicineHematologyOncologyHematologic OncologyStem Cell TransplantationTransplant ImmunologyChemotherapy In Hematologic MalignanciesConditioning RegimensEngraftment MonitoringHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematopoietic Stem Cell TransplantationAllogeneic Transplant ConditioningConditioning Dose AdjustmentHematopoietic Stem Cell Transplant ConditioningTransplantation For Hematologic MalignanciesTreosulfan-based Conditioning
In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination. Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received intravenous treosulfan, 12 g/m(2)/day (n = 5) or 14 g/m(2)/day (n = 55) on days -6 to -4, and Flu (30 mg/m(2)/day) on days -6 to -2, followed by infusion of marrow (n = 7) or peripheral blood stem cells (n = 53) from HLA-identical siblings (n = 30) or unrelated donors (n = 30). All patients engrafted. NRM was 5% at day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS) for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients.
46
John M. Bennett, Daniel Catovsky, Marie‐Theregse Daniel et al. · British Journal of Haematology · 1976 · 5.6K citations
Medicine, Hematology, Pathology +17
Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Alexandra H. Filipovich, Daniel J. Weisdorf, Steven Z. Pavletic et al. · Biology of Blood and Marrow Transplantation · 2005 · 3.5K citations